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ABSTRACT
A standardised antibiotic surveillance system is an essential requirement of all antibiotic control
strategies. Antibiotic use can be quantified accurately using patient-level surveillance, although this is
not feasible for most hospitals. Instead, population-level surveillance is a more realistic alternative for
ongoing and systematic monitoring of antibiotic use. Monitoring of aggregate, ward-supply data on a
monthly basis, stratification by patient care area, and analysis by the anatomical therapeutic
chemical ⁄defined daily dose (ATC ⁄DDD) system, adjusting for bed-occupancy, provides a clear picture
of antibiotic consumption density and time-trends within a hospital. When usage rates are supple-
mented and interpreted according to changes in hospital resource indicators, benchmarking is
facilitated. This provides an efficient tool for triggering and targeting antibiotic control interventions.
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Increasing use of antibiotics has been described in
hospital settings worldwide [1–3]. Estimates of
sub-optimal prescribing are of great concern,
indicating high proportions of unnecessary or
inappropriate prescriptions [4–6]. In addition to
increased direct healthcare costs, injudicious use
of antibiotics is considered to be a pivotal force in
the emergence of bacterial resistance.
The relationship between antibiotic use and
resistance is complex and difficult to assess.
Austin et al. [7] used population analysis methods
and mathematical models to demonstrate that
once a critical level of drug use is exceeded, the
emergence of resistance to significant levels is
triggered. Once this occurs, substantial reductions
or changes in antibiotic use will be necessary in
order to reverse the trend.
In response, several strategies (educational,
organisational and restrictive) to control antibiotic
use in hospitals have been developed to minimise
the selective pressure for development of resist-
ance. Despite controversies concerning which
method, or combination of methods, is more
effective [8,9], all methods require a standardised
antibiotic surveillance system. Only by providing
comparable surveillance data, efforts and re-
sources will it be possible to concentrate on the
most cost-effective approaches to the control of
antibiotic use.
Hospital antimicrobial use can be quantified
accurately using patient-level surveillance. This
involves collection of data concerning the dose,
dosage interval and duration of therapy. When
other patient-specific data are collected, such as
demographics, underlying disease states, patho-
gens involved and outcomes of antibiotic use, the
appropriateness of antibiotic therapy can also be
assessed [5,6]. However, it is likely that most
hospitals do not have computerised prescription
databases to facilitate the processing of such data,
which makes collection of patient-specific data
laborious and time-consuming, requiring extrac-
tion from handwritten case records [10]. With few
exceptions, patient-level data are obtained
through time-limited surveys or audits, and
therefore do not represent surveillance data.
In contrast, population-level surveillance refers
to the collection of aggregate antibiotic use data,
summarised at the level of a hospital or a ward.
Antibiotic dispensing data are available readily
from pharmacy stock control computers. Phar-
macies should be able to make appropriate
administrative corrections for returns, disposals
because of expiry, or exchanges among wards or
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third parties. Aggregate data should then provide
a reliable estimate of antibiotic consumption. In
most instances, population-level surveillance is
the only realistic alternative for ongoing and
systematic monitoring of antibiotic use [10].
Standardisation of data collection and process-
ing is crucial when surveying antibiotic use.
However, variation in units of measurement, data
sources, processing and presentation is common
in published surveillance studies (Table 1). Con-
siderable variation exists in the units used to
quantify antibiotic consumption at the population
level [10]. However, the anatomical therapeutic
chemical (ATC) classification and defined daily
dose (DDD) system meets the challenge of stand-
ardising the quantification of antibiotic use [11],
and this system is gradually becoming a standard
for benchmarking antibiotic use among institu-
tions. Notable examples of national surveillance
projects that have adopted this methodology
include DANMAP in Denmark [12], SWAB in
The Netherlands [13], SARI ⁄MABUSE in
Germany [1], and ICARE in the USA [14].
Nevertheless, standardisation problems arise in
the application of the ATC ⁄DDD system. A
European survey carried out by Ronning et al.
[15] identified inadequate references to the
ATC ⁄DDD version used, use of divergent ver-
sions, and divergent or unauthorised assignments
of DDDs. Compliance with the ATC ⁄DDD system
was also a major issue for the European Surveil-
lance of Antimicrobial Consumption pilot project
[16]. These studies also highlighted the fact that it
is difficult for many countries to supply reliable or
comparable hospital data.
In order to facilitate comparisons, it is neces-
sary to eliminate fluctuations in antimicrobial use
that reflect differences in population size over
time. This is accomplished by normalising the
DDD data into density rates. As recommended by
the WHO, the number of bed-days is chosen most
frequently as the denominator [11]. However, a
clear description of the methods used to calculate
bed-days (e.g., whether the days of admission and
discharge count together as one bed-day) is only
provided rarely, and additional terms, such as
occupied bed-days, census-days and patient-
days, are used frequently without precise defini-
tions [17,18]. Moreover, the debate as to the most
appropriate choice of denominator is ongoing.
A recent study from Dutch hospitals highlighted
the fact that antibiotic use presented as DDDs ⁄ Ta
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bed-day may not suffice to explain trends in
usage over time or between hospitals. Such rates
should be supplemented by hospital resource
indicators (e.g., number of beds, occupancy rates,
admissions per bed, bed-days and mean length of
stay) and interpreted according to changes in
these indicators. The number of DDDs ⁄ admission
should also be considered as an ancillary rate to
express antibiotic use [19].
Stratification of the data by specific populations
within the hospital (e.g., intensive care and
general ward patients, surgical and non-surgical
patients) is another issue requiring attention
when presenting antibiotic use rates. Most hospi-
tals are only able to state hospital-wide rates,
since patient-mix or limited pharmacy resources
render surveillance of individual patient care
areas difficult. However, studies that assess con-
sumption separately for different areas (mainly
by examining the intensive care units separately)
imply that sole reliance on hospital-wide data
could mask important patterns and time-trends
within individual areas [18,20,21].
An additional point worthy of consideration is
the frequency of data collection. Most hospitals
are only able to produce data on a yearly basis,
since this is the usual standard for presenting
management and financial information. However,
collection should occur over shorter time periods
to detect small variations and provide sufficient
statistical power to detect temporal trends in
usage rates. This is especially true when evaluat-
ing antibiotic control interventions [22], as well as
when studying the link to resistance data. Monnet
et al. [23] have suggested a minimum of 60 time-
intervals in order to use time-series analysis to
investigate relationships between use and resist-
ance. Monthly data collection provides a good
compromise between getting a sufficient number
of observations and sustaining feasibility of col-
lection.
Our own experience with antibiotic surveil-
lance at the University Hospital of Heraklion in
Greece has shown that aggregate, ward-supply
data represent the cornerstone for generative local
antibiotic policy management. Analysis by the
ATC ⁄DDD system, adjusting for bed-occupancy,
has provided a simple and objective measure of
prescribing. Data collection on a monthly basis for
a sufficient surveillance period, and stratification
of usage rates by patient care area, have enabled a
clear picture of antibiotic consumption density
and time-trends within the hospital to be ob-
tained. Moreover, comparison of data among
similar clinical services, and benchmarking with
the data available in the literature, has helped to
detect problem areas. Identification, with quanti-
tative evidence, of patient care areas with unusual
antibiotic consumption rates is an effective tool
when requesting additional resources for more
detailed (and resource-intensive) audits to assess
the appropriateness of use, and for analysing
time-trends in microbiological results. Conse-
quently, a streamlining programme (adjusting
initial antimicrobial therapy, based on microbio-
logical results and the clinical course) can be
applied in targeted areas within the hospital, and
forms the most suitable strategy to control anti-
biotic use and resistance.
In conclusion, antibiotic surveillance is an
essential part of rational decision-making on the
allocation of scarce resources towards improving
patient care. Population-level surveillance of
monthly ward-supply data is a good start
towards assessing patterns and time-trends in
antibiotic use. Standardisation of surveillance
methods is crucial in order to facilitate bench-
marking within and among institutions, and
provides an efficient tool for targeting detailed
audits and triggering antibiotic policy enhance-
ments.
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